Division of Transplantation, Washington Hospital Center, Washington, DC 20010, USA.
Clin Transplant. 2013 May-Jun;27(3):E256-63. doi: 10.1111/ctr.12100. Epub 2013 Mar 11.
We are reporting the results over a 20 yr period of simultaneous pancreas-kidney transplants in patients with end-stage renal disease and diabetes mellitus. The outcomes of the transplants, performed between 1989 and 2008, are stratified by pretransplant c-peptide value.
One hundred and seventy-three patients with end-stage renal disease due to diabetes, and were stratified according to undetectable c-peptide (x < 0.8 ng/mL) and detectable c-peptide (x > 0.8 ng/mL) levels.
Patients with detectable c-peptide (x > 0.8 ng/mL) were the oldest at diabetes diagnosis (24.2 vs. 15.4 yr, p < 0.0001), and oldest at transplant (42.8 vs. 38.5, p < 0.0001) had fewer years of insulin use (19.19 vs. 22.57 yr, p = 0.012), and were heavier pre transplant (BMI: 26.09 vs. 23.1, p < 0.0001), and heavier post transplant (29.8 vs. 24.7, p < 0.0001). Those with detectable c-peptide levels (x > 0.8 ng/mL) had better graft survival than those with an undetectable c-peptide level (x < 0.8 ng/mL), p = 0.064; while those with undetectable levels, had better patient survival than those with detectable c-peptide levels (p = 0.019).
Despite the differences between groups by BMI, age of onset of insulin use, and age at transplant, there was a difference in patient but not graft survival within the 20 yr follow-up period.
我们报告了在过去 20 年中对患有终末期肾病和糖尿病的患者同时进行胰腺-肾脏移植的结果。根据移植前 C 肽值对这些移植的结果进行分层。
173 名患有糖尿病导致的终末期肾病的患者根据无法检测到的 C 肽(x < 0.8ng/ml)和可检测到的 C 肽(x > 0.8ng/ml)水平进行分层。
可检测到 C 肽(x > 0.8ng/ml)的患者在诊断糖尿病时年龄最大(24.2 岁 vs. 15.4 岁,p < 0.0001),在移植时年龄最大(42.8 岁 vs. 38.5 岁,p < 0.0001),胰岛素使用年限较少(19.19 年 vs. 22.57 年,p = 0.012),移植前体重较重(BMI:26.09 千克/平方米 vs. 23.1 千克/平方米,p < 0.0001),移植后体重较重(29.8 千克/平方米 vs. 24.7 千克/平方米,p < 0.0001)。可检测到 C 肽水平(x > 0.8ng/ml)的患者比无法检测到 C 肽水平(x < 0.8ng/ml)的患者的移植物存活率更好,p = 0.064;而无法检测到 C 肽水平的患者比可检测到 C 肽水平的患者的患者存活率更好,p = 0.019。
尽管在 BMI、开始使用胰岛素的年龄和移植时的年龄等方面存在差异,但在 20 年的随访期间,患者的生存率而非移植物的生存率存在差异。